TAILIEUCHUNG - Making Better Drugs for Children with Cancer

This report has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise, in accordance with procedures approved by the NRC’s Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published report as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process | Making Better Drugs for Children with Cancer Making Better Drugs for Children with Cancer Committee on Shortening the Time Line for New Cancer Treatments National Cancer Policy Board Peter C. Adamson Susan L. Weiner Joseph V. Simone and Hellen Gelband Editors INSTITUTE OF MEDICINE AND NATIONAL RESEARCH COUNCIL OF THE NATIONAL ACADEMIES THE NATIONAL ACADEMIES PRESS Washington . THE NATIONAL ACADEMIES PRESS 500 Fifth Street . Washington DC 20001 NOTICE The project that is the subject of this report was approved by the Governing Board of the National Research Council whose members are drawn from the councils of the National Academy of Sciences the National Academy of Engineering and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance. This study was supported by Contract No. NO2-CO-01029 between the National Cancer Institute and the National Academy of Sciences. Any opinions findings conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the organizations or agencies that provided support for this project. International Standard Book Number 0-309-09608-1 Book International Standard Book Number 0-309-54925-6 PDF Additional copies of this report are available from the National Academies Press 500 Fifth Street . Lockbox 285 Washington DC 20055 800 624-6242 or 202 334-3313 in the Washington metropolitan area Internet http . For more information about the Institute of Medicine visit the IOM home page at . Copyright 2005 by the National Academy of Sciences. All rights reserved. Printed in the United States of .

• Y học thường thức
• Broad Perspective
• Environmental Factors
• Environmental Chemical
• Physical Exposures
• Genetic Variability
• Breast Cancer
• BMC Cancer
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Breast cancer management
• Gross anatomy
• The breast
• Breast cancer epidemiology
• Hereditary breast cancer genetics
• Prediction techniques
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Breast specific gamma imaging
• Diagnosing breast cancer during
• Ductal carcinoma in situ
• DNA methylation
• Breast epithelial cells
• Breast cancer campaign tissue bank
• Breast milk
• Axillary lymph node dissection
• Breast cancer related lymphedema
• Breast lymphatics level
• Ovarian cancer
• Mauritanian breast cancer patients
• Triple negative breast cancer
• Molecular subtype
• Cholesterol observed
• Female breast cancer
• Breast feeding
• World Health Organization
• Inflammatory breast cancer
• Case comparison study
• Family history of breast cancer
• Breast cancer risk factors
• Multiplex IBC families
• Carcinoma associated fibroblasts
• Breast cancer pathogenesis
• Breast cancer cell biology
• Cytokine molecules mediating
• Stage IV breast cancer
• Metastatic breast cancer
• Diagnostic marker
• Searching reliable
• Protein cancer biomarkers
• Breast fluid secretome
• breast cancer second edition
• Breast Sonography
• Radionuclide Imaging of the Breast
• Mammography
• Breast Reconstruction
• Chemotherapy for Breast Cancer
• Breast imaging
• Breast pathology
• Breast soft tissue
• Breast cancers
• Breast tumorigenesis
• Non steroidal anti inflammatory drug
• Hormone receptor positive breast cancer
• HER2 positive breast cancer
• Aggressive tumor phenotype
• Health care
• Including increased frequency
• Polygenic risk score
• Single nucleotide polymorphisms
• Artifcial neural network
• Estrogen receptor negative breast cancer
• Mammographic breast density
• Breast cancer risk
• Atypical hyperplasia
• Established risk factors
• Non melanoma skin cancer
• Metastatic cancer
• Reduce ethnic
• Multivariate models adjusting
• Cancer survivorship
• Cancer prevalence
• Statistical projection
• Toll like receptor 4
• +3725G C polymorphism
• Egyptian breast cancer atients
• Breast cancer cases than controls
• Post treatment breast cancer patients
• Pre treatment breast cancer
• Extraaxilary nodes
• Distance metastases
• Breast cancer cell lines
• Breast tumor subtypes
• Topoisomerase I
• Camptothecin sensivity
• Epithelial type
• Triplenegative breast carcinomas
• N terminal p63 isoforms